Company Viking Therapeutics, Inc.

Equities

VKTX

US92686J1060

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
79.58 ^USD	+5.52%		+22.56%	+327.62%

Apr. 25	Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday	MT
Apr. 24	Viking Therapeutics Q1 Loss Widens; Shares Fall After Hours	MT

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The Company is developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is also developing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of various metabolic disorders.

Number of employees: 28

Managers	Title	Age	Since
Brian Lian FOU	Founder	58	12-09-23
Gregory Zante DFI	Director of Finance/CFO	53	16-01-04
Marianne Mancini COO	Chief Operating Officer	59	15-04-30
Michael Morneau ADM	Chief Administrative Officer	58	14-04-30

Members of the board	Title	Age	Since
Matthew Foehr BRD	Director/Board Member	51	14-04-30
J. Singleton BRD	Director/Board Member	71	14-04-30
Charles Rowland BRD	Director/Board Member	65	17-06-30
Lawson Macartney CHM	Chairman	66	14-04-30
Brian Lian FOU	Founder	58	12-09-23
S. Rouan BRD	Director/Board Member	61	19-06-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	110,268,210	103,616,038 ( 93.97 %)	0	93.97 %

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 13.72 %	15,004,340	13.72 %	1 230 M $
BlackRock Advisors LLC 6.594 %	7,211,415	6.594 %	591 M $
STATE STREET CORPORATION 5.242 %	5,732,990	5.242 %	470 M $
Vanguard Fiduciary Trust Co. 4.921 %	5,381,904	4.921 %	441 M $
Viking Global Investors LP 4.705 %	5,145,112	4.705 %	422 M $
AllianceBernstein LP 3.360 %	3,673,935	3.360 %	301 M $
LIGAND PHARMACEUTICALS INCORPORATED 3.307 %	3,616,077	3.307 %	297 M $
Brian Lian 2.073 %	2,266,453	2.073 %	186 M $
Balyasny Asset Management LP 2.052 %	2,243,523	2.052 %	184 M $
American Century Cos., Inc. 2.034 %	2,223,822	2.034 %	182 M $

Viking Therapeutics, Inc.

9920 Pacific Heights Boulevard Suite 350

92121, San Diego

+858 704 4660

http://www.vikingtherapeutics.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

79.58 USD

Average target price

108.4 USD

Spread / Average Target

+36.27%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VIKING THERAPEUTICS, INC.	+327.62%	8.78B
VERTEX PHARMACEUTICALS INCORPORATED	-3.46%	102B
REGENERON PHARMACEUTICALS, INC.	+1.41%	96.09B
ARGENX SE	+2.13%	22.28B
BIONTECH SE	-15.84%	21.4B
GENMAB A/S	-9.21%	18.14B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-14.65%	16.09B
NEUROCRINE BIOSCIENCES, INC.	+4.39%	13.83B
SAREPTA THERAPEUTICS, INC.	+31.35%	11.97B

Bio Therapeutic Drugs